View Cart  

Jennerex Phase II Trial of JX594 Meets Key Clinical Endpoints

A A
Jennerex has announced positive clinical data from Phase II trial of JX594, a proprietary, engineered oncolytic immunotherapy, in sorafenib-refractory hepatocellular carcinoma (liver cancer, HCC) patients.
Pharmaceutical Business Review